Reply to E.C. Smyth et al and E. Elimova et al
- PMID: 26077234
- DOI: 10.1200/JCO.2014.60.5550
Reply to E.C. Smyth et al and E. Elimova et al
Comment on
-
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.J Clin Oncol. 2014 Nov 1;32(31):3520-6. doi: 10.1200/JCO.2013.54.1011. Epub 2014 Oct 6. J Clin Oncol. 2014. PMID: 25287828 Clinical Trial.
-
Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be?J Clin Oncol. 2015 Jul 20;33(21):2410. doi: 10.1200/JCO.2014.59.8847. Epub 2015 Jun 15. J Clin Oncol. 2015. PMID: 26077236 No abstract available.
-
Epirubicin, Cisplatin, and Capecitabine Versus Fluorouracil, Leucovorin, and Irinotecan for Esophagogastric Cancer: The Original and the Rest.J Clin Oncol. 2015 Jul 20;33(21):2409. doi: 10.1200/JCO.2014.59.7088. Epub 2015 Jun 15. J Clin Oncol. 2015. PMID: 26077239 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical